[Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].
Fiche publication
Date publication
juillet 2017
Journal
Presse medicale (Paris, France : 1983)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr NARDIN Charlée
Tous les auteurs :
Jacquin-Porretaz C, Nardin C, Puzenat E, Roche-Kubler B, Aubin F,
Lien Pubmed
Résumé
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules.
Mots clés
Antibodies, Monoclonal, adverse effects, CTLA-4 Antigen, antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung, drug therapy, Carcinoma, Renal Cell, drug therapy, Genes, cdc, drug effects, Guideline Adherence, Immunotoxins, adverse effects, Kidney Neoplasms, drug therapy, Lung Neoplasms, drug therapy, Melanoma, drug therapy, Neoplasm Metastasis, Programmed Cell Death 1 Receptor, antagonists & inhibitors, Skin Neoplasms, drug therapy
Référence
Presse Med. 2017 Jul;: